Targeted drug delivery for cancer therapy: the other side of antibodies

Therapeutic monoclonal antibody (TMA) based therapies for cancer have advanced significantly over the past two decades both in their molecular sophistication and clinical efficacy. Initial development efforts focused mainly on humanizing the antibody protein to overcome problems of immunogenicity an...

Descripción completa

Detalles Bibliográficos
Autores principales: Firer, Michael A, Gellerman, Gary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508879/
https://www.ncbi.nlm.nih.gov/pubmed/23140144
http://dx.doi.org/10.1186/1756-8722-5-70

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508879/
https://www.ncbi.nlm.nih.gov/pubmed/23140144
http://dx.doi.org/10.1186/1756-8722-5-70

Ejemplares similares